期刊文献+

血清HE4,CA125与TSGF联合检测在卵巢恶性肿瘤诊断中的价值 被引量:4

下载PDF
导出
摘要 目的探讨血清附睾蛋白4(HE4)、肿瘤抗原(CA125)与恶性肿瘤特异性生长因子(TSGF)联合检测在卵巢恶性肿瘤诊断中的临床价值。方法选取卵巢肿瘤患者192例为观察组,经术后病理诊断分为2组,卵巢良性肿瘤患者127例为观察Ⅰ组,卵巢恶性肿瘤患者65例为观察Ⅱ组,选取同期健康体检妇女80例为对照组,所有人员行血清HE4、CA125、TSGF测定。结果观察Ⅱ组HE4、CA125、TSGF水平均明显高于对照组和观察Ⅰ组,观察Ⅰ组HE4、CA125、TSGF水平均明显高于对照组。观察Ⅱ组患者中,肿瘤Ⅱ期、Ⅲ期患者HE4、CA125、TSGF水平均明显高于肿瘤Ⅰ期患者,淋巴结转移患者HE4、CA125、TSGF水平均明显高于未转移患者,肿瘤复发患者HE4、CA125、TSGF水平均明显高于未复发患者。特异性由高到低依次为HE4、联合诊断、TSGF、CA125,敏感性由高到低依次为联合诊断、CA125、TSGF、HE4,准确性由高到低依次为联合诊断、HE4、TSGF、CA125。结论血清HE4、CA125与TSGF联合检测可明显提高卵巢恶性肿瘤的诊断率,具有较高的临床价值,值得临床推广使用。
作者 周善良
出处 《现代中西医结合杂志》 CAS 2012年第31期3500-3501,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献9

二级参考文献42

共引文献54

同被引文献45

  • 1田满福.检测CAl99、CAl25、CAl53及CEA在肿瘤诊断中的意义[J].临床实验医学杂志,2010,4(9):483-485. 被引量:1
  • 2Mai PL,Wentzensen N,Greene MH. Challenges related to develo- ping serum based biomarkers for early ovarian cancer detection [J]. Cancer Prey Res(Phila) ,2011,4(3) :303- 306. 被引量:1
  • 3Moore RG, Mcmeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of o- varian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2009,112(1) :40-46. 被引量:1
  • 4Montagnana M,Danese E, Giudici S, etal. HE4 in ovarian cancer: from discovery to clinical application [J]. Adv Clin Chem, 2011,55 (1) :1-20. 被引量:1
  • 5Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian eancer[J].Caneer Biomark,2011,9(1-6):287-305. 被引量:1
  • 6Moore RG, MacLanghlan S, Bast Re Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer[J] Gynecol Oncol,2010,16(2):240-245. 被引量:1
  • 7Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer PrevRes (Phila) , 2011, 4: 1356-1359. 被引量:1
  • 8Moore RG, Jabore-Raughley M, Brown AK, Comparison of a novel multiple marker assay risk of malignancy index for the prediction of ovarian cancer in patients with a pelvicmess epl [J]. et al. vs the thelial Am JObstetGynecol,2010,2013 (3) :1-6. 被引量:1
  • 9BUYS S S, PARTRIDGE E, BLACK A, et al. Effect of screening on ovarian cancer mortality : the prostate, lung, colorectal and ovarian(PLCO) cancer screening random- ized controlled trial [ J ~. JAMA,2011,305 (22) :2295. 被引量:1
  • 10MOORE R G, MACLAUGHLAN S, BAST R J. Current state of biomarker development for clinical application in epithe- lial ovarian caneer[J3. Gynecol Oncol,2010,U6(2):240. 被引量:1

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部